QuVa Pharma Announces New, Innovative Syringe Labels

Company launches new syringe flag labels to help raise patient safety and to reduce the risk of drug and dosing errors— Sugar Land, TX – November 11, 2019 – QuVa Pharma, Inc. announced today that is has launched a new flag label design for its syringe product portfolio of compounded sterile products (CSPs) for which […]

QuVa Pharma Announces Immediate Significant Capacity Increase for Compounded Sterile Injectable Preparations

— Company more than doubles capacity at its New Jersey location through additional production, post compounding and distribution capabilities — SUGAR LAND, TX – September 26, 2019 – QuVa Pharma, Inc. today announced it is completing the next phase of capacity expansion at its Bloomsbury, New Jersey, state-of-the-art cGMP compliant 503B FDA registered manufacturing facility. […]

QuVa Pharma awarded National Outsourced I.V. Admixture Services Agreement with Premier

Sugar Land, TX – December 5, 2018 – QuVa Pharma, Inc. a leading FDA registered 503B outsourcing provider of “ready-to-use” compounded I.V. products, announced today that it has been awarded a group purchasing agreement for Outsourced I.V Admixture Services with Premier. Effective January 1st 2019, this new agreement allows Premier members to take advantage of […]

QuVa Pharma Announces Significant New Production Capacity Is Now Operational

 – Company opens new production suites in New Jersey facility, representing a 50% increase in company-wide capacity to compound sterile products –     Sugar Land, TX – September 26, 2018 – QuVa Pharma, Inc. today announced it has commenced manufacturing in newly completed Suites 4 & 5 at its facility in Bloomsbury, New Jersey, substantially […]

Eyeing The Future, QuVa Pharma Announces Successful Capital Raise

Company raises $41 million to support investments in 2019 capacity amid accelerating demand; cements itself as a national leader with near term path to 240,000 sq. ft. of production capacity — Sugar Land, TX – July 24, 2018 – QuVa Pharma, Inc. today announced it has raised additional debt funding of up to $41 million […]

QuVa Pharma in Training Program for First Responders in Terror Events

— Bloomsbury, NJ facility used for Special Operations “active shooter” exercise—    Sugar Land, TX – Mar 6, 2018 — QuVa Pharma, Inc. today announced that it has partnered with local law enforcement and special operations units to provide use of its Bloomsbury, New Jersey Facility to support the surrounding counties Special Operations First Responder Training […]

Amid Rapid Growth, QuVa Pharma Announces New Equity and Debt Funding

  – Company raises $40 million in new equity and debt to support capacity investments to meet accelerating demand for QuVa Pharma products; cements itself as an industry leader  – Sugar Land, TX – January 31, 2018 — QuVa Pharma, Inc. today announced it has raised additional debt and equity funding of up to $40 […]

QuVa Pharma Partners with WCCC on Job Opportunities

BLOOMSBURY (Jan. 24, 2018) – When QuVa Pharma started operations at its Northeast facility in July 2017 in Bloomsbury, officials wanted to make an impact on the regional community with jobs and other support efforts. It has done just that in six months. Arguably, the partnership between QuVa and Warren County Community College (WCCC) may have the most far-reaching […]

QuVa Pharma Announces Its Ability to Supply Hydromorphone and Morphine Pre-Filled Syringes

-Compounded Hydromorphone and Morphine syringes are expected to help alleviate drug shortages impacting the nation’s hospitals- There is a nation-wide shortage of pre-filled syringe presentations of hydromorphone and morphine. This shortage is expected to persist for a number of months. QuVa Pharma, Inc. is pleased to announce that it has available supplies of: Hydromorphone 1mg/ml […]

QuVa Pharma Announces FDA 503B Registration of its New Jersey Facility

Initial Phase of 160,000SF building redevelopment complete and facility to commence shipping product in September 2017 Sugar Land, TX – September 26th, 2017 – QuVa Pharma, Inc. a national supplier of sterile compounding services driving new quality standards in the industry, today announced it has received FDA registration as a 503B facility for its Bloomsbury, […]